Product nomen: Levobupivacaine hydrochloride,Levobupivacaine Hcl
Synonyma: (S)-(-)-Bupivacaine Hydrochloride
Nec.: 27262-48-2
stipare: 25kg/orum
M.F.: C18H29ClN2O
M.W.: 324.8887
Aspectus: Album pulveris crystallini
Levobupivacaine (riNN) est locus Papaver medicamento ad amino amid group. Est S-enantiomer de bupivacaine. In hydrochloride sal levobupivacaine., amide inde cum anaesthetic rem. Levobupivacaine reversibly alligat canales sodium voltage-gatum ad fluxum ionicum modulandum et ne initiationem et transmissionem motus nervus. (stabiliens neuronal membrana), ita fit in analgesia et anesthesia. Prae racemic bupivacaine, levobupivacaine minus vasodilationi coniungitur et actionis longiorem durationem habet.
Levobupivacaine est amide-genus loci Papaver. Levobupivacaine acts via blockade of voltage-sensitive ion channels in neuronal membranes, preventing transmission of nerve impulses. Localised and reversible anaesthesia is produced by interference with the opening of the sodium channel, which inhibits conduction of the action potential in nerves involved in sensory and motor activity and sympathetic activity. [1] Levobupivacaine displaces 3H-BTX from sodium channels of rat brain synaptosomes with IC50 of 2.9 μM and Hill coefficients of 1.2. When cell membrane is held at -80 mV*, -70 mV*, -60 mV or -100 mV*, Levobupivacaine shows tonic inhibition of sodium channel in GH3 cells with IC50s of 132.1, 37.6, 21.6 et 264 μM, respectively. [2] Levobupivacaine depresses action potential of isolated axon in vitro.
Levobupivacaine HCl is intended for single use and does not contain preservatives; aliqua solutio manens ab vase aperto abicienda est. Pro certis technicis et processibus, ad vexillum hodiernae textu. Levobupivacaine compatibilitas et admixtus: Levobupivacaine non compatitur cum solutionibus alkalinis habens pH majus 8.5. Studia ostendimus levobupivacaine stare cum 0.9% Sodium Chloride Iniectio USP et cum solutionibus salinarum morphinum continens, fentanyl et clonidine. Compatibilitas studia cum aliis productis parentealibus non sunt quaesita. Dilutio Stabilitas: Levobupivacaine dilutum ad levobupivacaine 0.625 to 2.5 mg/mL in 0.9% sodium chloridum iniectio physice et chemica stabilis cum condita in polyvinyl chloride (PVC) sacculos ambientium locus temperatus usque ad 24 horae. Ars asetica adhibenda est producta diluta praeparanda. Mixtura ex leviobupivacaine praeparari debet ad unum tantum usum patientis et intus utendum 24 horae praeparationis. Pars insueta levobupivacaine diluti post unumquemque usum secerni debet.
